跳至主要内容
临床试验/NCT00593918
NCT00593918已完成不适用

Innate Immunity and RSV Infection in Children

University of Wisconsin, Madison1 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2003年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
91
试验地点
1
主要终点
Nasal Interferon (IFN)-a2

研究概览

简要总结

In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.

详细描述

Infection with RSV is the most common cause of respiratory tract illnesses (LRIs) in the first 3 years of life. There are significant social and health care costs associated with RSV-LRIs. More than 3% of US children are hospitalized each year due to RSV and 500 die annually. Several longitudinal studies have also suggested that children who have RSV-LRIs are at substantially increased risk of developing asthma in the first 3 years after infection and bronchial hyperresponsiveness (BHR) many years after the primary infection. Mechanisms involved in RSV disease are not well understood. Recent reports suggest that RSV may initiate the innate immune response through the pattern recognition receptor, Toll like receptor-4 (TLR4). In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production. It has been suggested that such a mechanism may result in altered immune responses to RSV infection and different clinical outcomes. This research has direct application to improving our understanding of bronchiolitis in early childhood, particularly those factors that influence severity of the disease, and may have implications for possible therapy of patients with bronchiolitis in the future.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
— 至 24 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Parental or sibling history of asthma.
  • Child must be less than 24 months of age.
  • Presence of viral upper or lower respiratory tract symptoms.

排除标准

  • History of recurrent wheezing requiring systemic corticosteroids.
  • Prior history of lung disease.
  • Birth < 36 weeks gestation.
  • Immunodeficiency
  • Treatment with ribavirin, systemic or inhaled corticosteroids during the RSV infection.
  • Congenital heart disease.
  • No history of parental or sibling asthma.
  • Less than 48 hour or more than 5 day duration of viral URI symptoms since the peak symptoms from RSV would be expected to occur from 2-5 days into course of infection.

结局指标

主要结局

Nasal Interferon (IFN)-a2

时间窗: 1-5 days during acute illness (not after day 5 of illness)

Interferon a2 was measured from nasal lavage samples by Luminex multiplex assay.

Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression

时间窗: 1-5 days during acute illness (not after day 5 of illness)

IL-2 measured from nasal lavage samples by Luminex multiplex assay

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验